Literature DB >> 17646339

Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles.

Marko Sysi-Aho1, Aki Vehtari, Vidya R Velagapudi, Jukka Westerbacka, Laxman Yetukuri, Robert Bergholm, Marja-Riitta Taskinen, Hannele Yki-Järvinen, Matej Oresic.   

Abstract

MOTIVATION: Serum lipids have been traditionally studied in the context of lipoprotein particles. Today's emerging lipidomics technologies afford sensitive detection of individual lipid molecular species, i.e. to a much greater detail than the scale of lipoproteins. However, such global serum lipidomic profiles do not inherently contain any information on where the detected lipid species are coming from. Since it is too laborious and time consuming to routinely perform serum fractionation and lipidomics analysis on each lipoprotein fraction separately, this presents a challenge for the interpretation of lipidomic profile data. An exciting and medically important new bioinformatics challenge today is therefore how to build on extensive knowledge of lipid metabolism at lipoprotein levels in order to develop better models and bioinformatics tools based on high-dimensional lipidomic data becoming available today.
RESULTS: We developed a hierarchical Bayesian regression model to study lipidomic profiles in serum and in different lipoprotein classes. As a background data for the model building, we utilized lipidomic data for each of the lipoprotein fractions from 5 subjects with metabolic syndrome and 12 healthy controls. We clustered the lipid profiles and applied a regression model within each cluster separately. We found that the amount of a lipid in serum can be adequately described by the amounts of lipids in the lipoprotein classes. In addition to improved ability to interpret lipidomic data, we expect that our approach will also facilitate dynamic modelling of lipid metabolism at the individual molecular species level.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646339     DOI: 10.1093/bioinformatics/btm181

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  6 in total

Review 1.  Lipidomics as a tool for the study of lipoprotein metabolism.

Authors:  Anatol Kontush; M John Chapman
Journal:  Curr Atheroscler Rep       Date:  2010-05       Impact factor: 5.113

2.  Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes.

Authors:  M Ståhlman; H T Pham; M Adiels; T W Mitchell; S J Blanksby; B Fagerberg; K Ekroos; J Borén
Journal:  Diabetologia       Date:  2012-01-18       Impact factor: 10.122

3.  Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders.

Authors:  Estela Area-Gomez; H Mitsumoto; D Larrea; T Yun; Y Xu; J Hupf; F Zandkarimi; R B Chan
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

4.  Lipid level alteration in human and cellular models of alpha synuclein mutations.

Authors:  Hila Avisar; Cristina Guardia-Laguarta; Matthew Surface; Nikos Papagiannakis; Matina Maniati; Roubina Antonellou; Dimitra Papadimitriou; Christos Koros; Aglaia Athanassiadou; Serge Przedborski; Boaz Lerner; Leonidas Stefanis; Estela Area-Gomez; Roy N Alcalay
Journal:  NPJ Parkinsons Dis       Date:  2022-04-25

5.  Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients.

Authors:  Juergen Graessler; Dominik Schwudke; Peter E H Schwarz; Ronny Herzog; Andrej Shevchenko; Stefan R Bornstein
Journal:  PLoS One       Date:  2009-07-15       Impact factor: 3.240

6.  A lipidomic analysis approach to evaluate the response to cholesterol-lowering food intake.

Authors:  Ewa Szymańska; Ferdinand A van Dorsten; Jorne Troost; Iryna Paliukhovich; Ewoud J J van Velzen; Margriet M W B Hendriks; Elke A Trautwein; John P M van Duynhoven; Rob J Vreeken; Age K Smilde
Journal:  Metabolomics       Date:  2011-12-07       Impact factor: 4.290

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.